2025 Japan Anti-Tuberculosis Drug Market Revenue Opportunities Report
Description
The 2025 Japan Anti-Tuberculosis Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Tuberculosis Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-tuberculosis (TB) drug market in Japan are Johnson & Johnson, Otsuka Pharmaceutical, Sanofi, and GlaxoSmithKline. Johnson & Johnson is notable for its product SIRTURO® (bedaquiline), a drug approved for multidrug-resistant TB and integrated into global and Japanese treatment protocols. Otsuka Pharmaceutical, headquartered in Tokyo, developed Deltyba (delamanid), another key drug targeting multidrug-resistant TB and is involved in advanced R&D with support from the Bill & Melinda Gates Foundation for novel compounds against TB. Sanofi and GlaxoSmithKline contribute through their global TB treatment efforts, with GSK also participating in the PAN-TB collaboration aiming to develop simplified regimens for resistant TB strains applicable in Japan.
These companies leverage innovation, extensive research, and partnerships to address TB challenges, including drug resistance. Johnson & Johnson has implemented pricing strategies to expand access in low- and middle-income countries, which impacts their global influence including markets like Japan. Otsuka continues pipeline development with compounds like OPC-167832 to potentially revolutionize TB treatment with oral regimens suitable for broad patient profiles. Sanofi and GSK, with their international reach, support Japan’s robust healthcare system and aging demographics by offering therapeutic options that align with WHO guidelines and national TB control programs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Tuberculosis Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-tuberculosis (TB) drug market in Japan are Johnson & Johnson, Otsuka Pharmaceutical, Sanofi, and GlaxoSmithKline. Johnson & Johnson is notable for its product SIRTURO® (bedaquiline), a drug approved for multidrug-resistant TB and integrated into global and Japanese treatment protocols. Otsuka Pharmaceutical, headquartered in Tokyo, developed Deltyba (delamanid), another key drug targeting multidrug-resistant TB and is involved in advanced R&D with support from the Bill & Melinda Gates Foundation for novel compounds against TB. Sanofi and GlaxoSmithKline contribute through their global TB treatment efforts, with GSK also participating in the PAN-TB collaboration aiming to develop simplified regimens for resistant TB strains applicable in Japan.
These companies leverage innovation, extensive research, and partnerships to address TB challenges, including drug resistance. Johnson & Johnson has implemented pricing strategies to expand access in low- and middle-income countries, which impacts their global influence including markets like Japan. Otsuka continues pipeline development with compounds like OPC-167832 to potentially revolutionize TB treatment with oral regimens suitable for broad patient profiles. Sanofi and GSK, with their international reach, support Japan’s robust healthcare system and aging demographics by offering therapeutic options that align with WHO guidelines and national TB control programs.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
